Member Info for neilrich3

Today is the first day that Pillar 1 capacity exceeded 200,000 tests.

Can't imagine that DHSC and PHE would not extend/renew in the midst of a deadly pandemic, not when they've spent the past 12 months increasing testing capacity. End of the day NCYT is a key player and world leader within the COVID diagnostics sector. Fairly confident that the contract shall be extended, pillar 1 testing ain't going anywhere.

Absolutely, brokers aren't that good, the 2024 forecast means very little at present and it shall be amended regularly going forward.

It's in the contract:
5 Variation of the Goods
5.2 Due to the rapidly evolving nature of the COVID-19 response, updated and improved versions of the goods may be developed /launched in the future which the authority may wish to purchase. The parties agree that where such new products are made available by the supplier, they may be ordered by the authority under the terms of this agreement at the same price per reaction a (or less than) the price listed for the original good.

https://neighborwebsj.com/uncategorized/2344750/comprehensive-report-on-%EF%BB%BFdna-extraction-kits-market-2021-size-growth-demand-opportunities-forecast-to-2027-thermo-fisher-scientific-promega-primerdesign-bioneer-pcr-biosystems/

Bluelight, NCYT are not allowed to publicise or provide updates concerning the DHSC contract, hence the radio silence, as per their contract.

Interesting, although does not refer to the company concerned, however it could be Novacyt, this might be one of the exciting new products.

JUNGLA, My understanding is that DHSC are paying £7 a test maximum.

Wonder whether the potential DHSC Phase 2 could focus upon educational establishments and less so upon care homes?

With vaccines not approved for children and the need to get schools open and keep them open, I envisage a requirement for a system of weekly testing and screening, something which would have to be kept in place for many years.

Moonpig has been valued at >30 earnings, not sure how much cash in the bank, however overvalued in my book. There's a limit to what you can do with a greetings card and as you say their market is relatively small.

SODER, You don't think that Moonpig has been boosted by the Pandemic? Yet the market has chosen to ignore any potential downside in a post COVID world.

CB1984, I think you're missing my point.

Moonpig soared above its £1.2bn valuation on its stock market debut, with shares in the online card retailer jumping by almost a third.
Moonpig, which is eyeing a place in London's FTSE 250 Index. It chalked up sales of £173m and underlying profits of £44m for the 12 months to April 2020.

Just attempting to draw a comparison with our crazy valuation.

I agree Hartlebury, NCYT involvement with Global research is a massively important and could lead to additional business from foreign government.

Sorry, however the line below suggests that it is not NCYT. If PHE was using the new SNPSIg there be no need to send positive samples for further testing, they'd know after the first test, that's the whole idea.

'All of the swabs confirmed to have Covid will be sent to labs for further testing'

Why would this speed up DHSC phase 2? DHSC phase 1 is perfectly safe and an extension to that shall come before phase 2.

BING007. The first three SNPsig® assays, launched today!!

https://twitter.com/investographer/status/1355803466791325698/photo/1

Chris Harrigan tweet effectively leaked Today's announcement and some questioned why he took it down.

"SNPSIG" was quoted in the Chris Harrigan tweet at the weekend being compatible with ProMate.

PHE shall be front of the Q to purchased this, followed by just about every other country in the developed world.

OMG! This is massive and the timing of it.